Immunocellular Therapeutics Stock Shares Outstanding
ImmunoCellular Therapeutics fundamentals help investors to digest information that contributes to ImmunoCellular Therapeutics' financial success or failures. It also enables traders to predict the movement of ImmunoCellular Pink Sheet. The fundamental analysis module provides a way to measure ImmunoCellular Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoCellular Therapeutics pink sheet.
ImmunoCellular |
ImmunoCellular Therapeutics Company Shares Outstanding Analysis
ImmunoCellular Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ImmunoCellular Therapeutics Shares Outstanding | 4.19 M |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, ImmunoCellular Therapeutics has 4.19 M of shares currently outstending. This is 97.68% lower than that of the Biotechnology sector and 96.08% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.27% higher than that of the company.
ImmunoCellular Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.ImmunoCellular Therapeutics is currently under evaluation in shares outstanding category among its peers.
ImmunoCellular Fundamentals
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 933.15 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.78 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 1.51 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (2.31 M) | ||||
| Short Ratio | 4.13 X | ||||
| Earnings Per Share | 28.91 X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 2.21 M | ||||
| Total Asset | 30.08 M | ||||
| Retained Earnings | (74.14 M) | ||||
| Working Capital | 22.29 M | ||||
| Current Asset | 24.56 M | ||||
| Current Liabilities | 2.27 M | ||||
| Z Score | -2.8 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |